Rekah Pharmaceutical Industry Ltd.

As of June 30, 2026, Rekah Pharmaceutical Industry Ltd. carries a market capitalization of 12.17B, placing it among publicly traded companies globally. Its enterprise value stands at 23.69B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Rekah Pharmaceutical Industry Ltd. has 11.41M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.39, and the price-to-book ratio stands at 0.87.

As of June 30, 2026, Rekah Pharmaceutical Industry Ltd. trades at an EV/EBITDA multiple of 9.36 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.78 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 23.69B versus a market cap of 12.17B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Rekah Pharmaceutical Industry Ltd. maintains a current ratio of 1.41, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 87.34, indicating elevated leverage, while an interest coverage ratio of 4.55 demonstrates adequate ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 71.12M in revenue per employee across its workforce of 427.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Rekah Pharmaceutical Industry Ltd. recorded 612.50M in income tax expense. The company reported a pretax loss of -968.70M and -1.58B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Rekah Pharmaceutical Industry Ltd.'s stock has declined approximately 12.89% over the past 52 weeks. The 50-day moving average sits at 1,078.16, while the 200-day moving average is 1,123.32.

Over the twelve months ended June 30, 2026, Rekah Pharmaceutical Industry Ltd. generated 30.40B in revenue and converted that into -1.58B in net income, yielding earnings per share of -140.47. EBITDA reached 2.53B, while operating income came in at -606.40M.

As of June 30, 2026, Rekah Pharmaceutical Industry Ltd. holds 724.40M in cash and equivalents against 12.24B in total debt, resulting in a net debt position of 7.77B. Total book value stands at 14.01B, with working capital of 7.11B providing operational flexibility.

Rekah Pharmaceutical Industry Ltd. produced 2.80B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -515.90M in capital expenditures, free cash flow totaled 2.29B - equivalent to 203.25 per share.

Over the twelve months ended June 30, 2026, Rekah Pharmaceutical Industry Ltd. posted a gross margin of 22.57, reflecting its pricing power and cost economics. The operating margin of -1.99 and net profit margin of -5.20 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 19.07, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 15.58, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Rekah Pharmaceutical Industry Ltd. shareholders.

As of June 30, 2026, Rekah Pharmaceutical Industry Ltd. has an Altman Z-Score of 1.26, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.